NCT02293837: A reported trial by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02293837 |
|---|---|
| Title | Preserving Beta-Cell Function With Tocilizumab in New-onset Type 1 Diabetes (ITN058AI) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | March 12, 2015 |
| Completion date | July 10, 2019 |
| Required reporting date | July 10, 2022, midnight |
| Actual reporting date | July 22, 2021 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |